Notably, although a new treatment era for IBD has opened up with infliximab (IFX), adalimumab (ADA), and certolizumab, etc., 20% of the population is still unresponsive to anti-TNF therapy. The gene discussed is TNF; the disease is inflammatory bowel disease.